Result for
Tag: treatment
October 21, 2020
The Effect of Prior ACEI/ARB Treatment on COVID-19 Susceptibility and Outcome: A Systematic Review and Meta-Analysis
A systematic review and meta-analysis (49 studies) reported no association between treatment with angiotensin-converting enzyme inhibitors (ACEI) and/or angiotensin receptor blockers (ARB) and risk of SARS-CoV-2 infection (adjusted OR=1.00, 95%CI 0.94-1.05). The use of ACEI/ARB was also not associated with the risk of mortality (aOR=0.87, 95%CI 0.66-1.04) and severe outcomes (aOR=0.95, 95%CI 0.73-1.24). These findings…
October 20, 2020
Tocilizumab for Treating COVID-19: A Systemic Review and Meta-Analysis of Retrospective Studies
A systematic review of case-control (n=2,285 patients) and single-arm studies (n=208 patients) found that treatment with the immunomodulator tocilizumab (TCZ) in COVID-19 patients was associated with a lower risk of admission to ICU, invasive ventilation, and mortality compared with standard treatment. Patients who received TCZ had changes of several clinical indicators that marked higher rates…
Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial
A randomized open-label trial of treatment with the immune modulator tocilizumab (TCZ) in patients with COVID-19 pneumonia found that the rate of clinical worsening (entry to ICU unit with intubation, death from all causes, or clinical aggravation) was not significantly different among patients receiving tocilizumab (TCZ) (n=60) and those receiving standard of care (n=66) (RR=1.05;…
Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia
A randomized, open-label trial of patients with COVID-19 and pneumonia who required oxygen support but were not admitted to ICU found no statistically significant difference in mortality over 28 days between those receiving the immunomodulator tocilizumab (TCZ) (n=63) and those receiving standard of care (n=67). At day 14, the proportion of patients with noninvasive ventilation,…
October 19, 2020
Hydroxychloroquine as Pre-Exposure Prophylaxis for COVID-19 in Healthcare Workers: A Randomized Trial
Pre-exposure prophylaxis with hydroxychloroquine once or twice weekly did not significantly reduce COVID-19 or COVID-19-compatible illness among healthcare workers with ongoing exposure to people with SARS-CoV-2. The randomized, double-blind, placebo-controlled clinical trial of healthcare workers in the US and Canada found that for once weekly hydroxychloroquine prophylaxis, the hazard ratio for COVID-19 was 0.72 (95%CI…
October 16, 2020
Repurposed Antiviral Drugs for COVID-19 Interim WHO SOLIDARITY Trial Results
[Pre-print, not peer reviewed] Interim results for the original four drugs in the WHO Solidarity trial indicated that remdesivir, hydroxychloroquine, lopinavir/ritonavir and interferon regimens did not appear to reduce mortality, initiation of ventilation, or duration of hospital stay. Out of 11,266 adults in 30 countries who were randomized, 1,253 deaths were reported. Kaplan-Meier analysis of…
October 14, 2020
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults
The International Antiviral Society-USA panel released recommendations regarding antiretroviral therapy for both the treatment and prevention of HIV. These guidelines involve recommendations regarding when to start antiretroviral therapy, when to change regimens, and recommendations for specific subpopulations (e.g., elderly patients, patients with organ dysfunction). Highlights of changes from previous versions include new recommendations for initial…
October 12, 2020
Beneficial Effect of Corticosteroids in Preventing Mortality in Patients Receiving Tocilizumab to Treat Severe COVID-19 Illness
An observational retrospective analysis of the characteristics and risk factors for mortality in patients with severe COVID-19 treated with the immunomodulator tocilizumab (TCZ), with or without corticosteroids, found that mortality was associated with older age (HR=1.09), chronic heart failure (HR=4.4), and chronic liver disease (HR=4.69). 186 patients were treated with TCZ, among whom 129 were…
Compassionate Use of Remdesivir in Pregnant Women with Severe Covid-19
Among 86 pregnant and postpartum women with severe COVID-19 who received compassionate use of remdesivir, recovery rates were high (93% for pregnant women and 89% for postpartum women) and there were few serious adverse events (16% of all participants). At the beginning of treatment with remdesivir, 40% of pregnant women required invasive ventilation, compared to…
October 9, 2020
Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19
The RECOVERY trial found that patients hospitalized with COVID-19 who received hydroxychloroquine did not have a lower incidence of death by 28 days after enrollment compared to those who received usual care. The randomized open-label platform trial found that patients in the hydroxychloroquine group were less likely to be discharged from the hospital alive within…
Previous page Next page